Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 1
1996 1
1997 4
1998 2
1999 1
2000 1
2001 1
2002 4
2003 2
2004 2
2005 1
2007 3
2008 2
2009 2
2010 1
2011 5
2012 4
2013 7
2014 6
2015 6
2016 8
2017 6
2018 4
2019 5
2020 8
2021 10
2022 8
2023 4
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Birtas Atesoglu E, et al. Among authors: ferhanoglu b. Hematol Oncol. 2023 Oct;41(4):663-673. doi: 10.1002/hon.3174. Epub 2023 May 22. Hematol Oncol. 2023. PMID: 37211991
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Ardeshna KM, et al. Among authors: ferhanoglu b. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4. Lancet Oncol. 2014. PMID: 24602760 Clinical Trial.
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.
Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Northend M, et al. Among authors: ferhanoglu b. Lancet Haematol. 2025 May;12(5):e335-e345. doi: 10.1016/S2352-3026(25)00034-1. Lancet Haematol. 2025. PMID: 40306831 Free article. Clinical Trial.
Treatment of Mantle-Cell Lymphoma.
Ferhanoglu B, Birtas Atesoglu E, Ozbalak M. Ferhanoglu B, et al. N Engl J Med. 2022 Sep 22;387(12):1147. doi: 10.1056/NEJMc2209904. N Engl J Med. 2022. PMID: 36130008 No abstract available.
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients.
Mehtap Ö, Toptas T, Dal MS, Karadag FK, Atas U, Özsan GH, Sayınalp N, Saydam G, Uçar MA, Kırkızlar HO, Salim O, Tekinalp A, Özkalemkaş F, Pepedi F, Akay OM, Kılıçaslan E, Paydas S, Bozdağ SC, Yılmaz M, Karakus V, Arikan FG, Darçın T, Erdogan E, Cinar E, Gürsoy V, Durusoy SS, Birtaş Ateşoğlu E, Tombak A, Büyükkurt N, Özcan M, Altuntaş F, Kaygusuz Atagündüz I, Ferhanoglu B. Mehtap Ö, et al. Among authors: ferhanoglu b. Leuk Lymphoma. 2024 Dec;65(14):2190-2198. doi: 10.1080/10428194.2024.2395458. Epub 2024 Sep 13. Leuk Lymphoma. 2024. PMID: 39269267
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP, Arslan Ö, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz MG, Leber B, Montillo M, Panayiotidis P, Rossi D, Skarbnik A, Tempescul A, Turgut M, Mellink CH, van der Kevie-Kersemaekers AF, Lanham S, Sale B, Del Rio L, Popovic R, Chyla BJ, Busman T, Komlosi V, Wang X, Sail K, Pena GE, Vizkelety T, Forconi F. Kater AP, et al. Among authors: ferhanoglu b. Lancet Oncol. 2024 Apr;25(4):463-473. doi: 10.1016/S1470-2045(24)00070-6. Epub 2024 Mar 8. Lancet Oncol. 2024. PMID: 38467131 Free article. Clinical Trial.
103 results